Wednesday, March 27, 2024 COVID-19 mRNA Revaccination Is Safe After Allergic Reaction to First Dose, NIAID Trial Finds Transmission electron micrograph of SARS-CoV-2 virus particles (colorized gold) isolated from a patient sample. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A small NIAID clinical trial has found that receiving second and booster doses of a COVID-19 mRNA vaccine under medical supervision was safe for people who reported a systemic allergic reaction to their first dose. After revaccination, 12.5% of study participants had a systemic allergic reaction, while 62.5% had a non-allergic reaction that mimics anaphylaxis and is called Immunization Stress-Related Response (ISRR). These findings highlight the opportunity to assess and manage pre-vaccination anxiety to reduce ISRR. The results are published in the Journal of Allergy and Clinical Immunology. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107